Shares of Decibel Therapeutics, Inc. (DBTX) are up 78% on Wednesday after Regeneron Pharmaceuticals agreed to acquire Decibel at $4.00 per share, with an additional non-tradeable contingent value right (CVR) of $3.50 per share in cash if Decibel's DB-OTO achieves certain clinical development and regulatory milestones within specified time periods.
DBTX is trading on the Nasdaq at $4.99, up 78.85% or $2.20 per share. It has traded between $1.61 and $5.68 in the past 52-week period.
The proposed acquisition values Decibel at a total equity value of approximately $109 million and approximately $213 million if the CVR milestones are achieved.
DB-OTO, which is currently being tested in the global Phase 1/2 CHORD clinical trial is an investigational cell-selective adeno-associated virus (AAV) gene therapy that aims to restore hearing in individuals with otoferlin-related hearing loss.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.